Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial ...
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients ...
The risk of disease progression or death was reduced by 79% with nivolumab/ipilimumab compared with chemotherapy. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--Recognizing a need for evidence-based recommendations to guide molecular testing in the management of patients with cancer, the College of American Pathologists (CAP ...
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case ...
The most common form of colorectal cancer, microsatellite-stable colorectal cancer (MSS CRC), can currently only be treated to a limited extent with modern immunotherapies. A research team led by ...
Tumors with high levels of microsatellite instability (MSI-H), such as some subsets of colorectal, endometrial and gastric cancers, are associated with a hypermutated phenotype and a specific ...
Panakeia (“the Company”), a pioneer in AI-driven multi-omic biomarker profiling, today announces the launch of PANProfiler Colon, an AI-driven software solution for profiling of Microsatellite ...
On Monday, the FDA accepted the supplemental biologics license application (sBLA) for Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results